| Title |
The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease
|
|---|---|
| Published in |
Advances in Therapy, September 2019
|
| DOI | 10.1007/s12325-019-01086-2 |
| Pubmed ID | |
| Authors |
Joshua J. Solomon, Sonye K. Danoff, Hilary J. Goldberg, Felix Woodhead, Martin Kolb, Daniel C. Chambers, Donna DiFranco, Cathy Spino, Shana Haynes-Harp, Shelley Hurwitz, Elizabeth B. Peters, Paul F. Dellaripa, Ivan O. Rosas |
X Demographics
The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 22% |
| United States | 2 | 22% |
| India | 1 | 11% |
| France | 1 | 11% |
| Unknown | 3 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 33% |
| Science communicators (journalists, bloggers, editors) | 3 | 33% |
| Scientists | 2 | 22% |
| Practitioners (doctors, other healthcare professionals) | 1 | 11% |
Mendeley readers
The data shown below were compiled from readership statistics for 70 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 70 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 6 | 9% |
| Student > Bachelor | 6 | 9% |
| Student > Ph. D. Student | 5 | 7% |
| Researcher | 5 | 7% |
| Student > Postgraduate | 5 | 7% |
| Other | 8 | 11% |
| Unknown | 35 | 50% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 25 | 36% |
| Nursing and Health Professions | 2 | 3% |
| Agricultural and Biological Sciences | 2 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 1% |
| Social Sciences | 1 | 1% |
| Other | 3 | 4% |
| Unknown | 36 | 51% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 June 2021.
All research outputs
#3,685,114
of 23,163,378 outputs
Outputs from Advances in Therapy
#333
of 2,387 outputs
Outputs of similar age
#72,724
of 340,823 outputs
Outputs of similar age from Advances in Therapy
#12
of 71 outputs
Altmetric has tracked 23,163,378 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,387 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.4. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 340,823 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 71 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.